Scott M. Giacobello - Mar 1, 2025 Form 4 Insider Report for Aadi Bioscience, Inc. (AADI)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Stephen Rodin, as Attorney-in-Fact
Stock symbol
AADI
Transactions as of
Mar 1, 2025
Transactions value $
-$6,594
Form type
4
Date filed
3/3/2025, 08:38 PM
Previous filing
Mar 4, 2024
Next filing
Apr 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AADI Common Stock Options Exercise +6.75K +33.75% 26.8K Mar 1, 2025 Direct F1
transaction AADI Common Stock Sale -$6.59K -2.81K -10.49% $2.35 23.9K Mar 3, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AADI Restricted Stock Units Options Exercise $0 -6.75K -25% $0.00 20.3K Mar 1, 2025 Common Stock 6.75K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock.
F2 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024.